Biogen Idec Inc (BIIB): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biogen Idec ( BIIB) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 3.1%. By the end of trading, Biogen Idec fell $12.25 (-3.9%) to $300.39 on heavy volume. Throughout the day, 2,092,827 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,321,800 shares. The stock ranged in price between $298.15-$316.99 after having opened the day at $314.84 as compared to the previous trading day's close of $312.64. Other companies within the Health Care sector that declined today were: Oramed Pharmaceuticals ( ORMP), down 24.1%, Galena Biopharma ( GALE), down 19.9%, Vanda Pharmaceuticals ( VNDA), down 16.0% and PTC Therapeutics ( PTCT), down 14.5%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $75.2 billion and is part of the drugs industry. The company has a P/E ratio of 35.5, above the S&P 500 P/E ratio of 17.7. Shares are up 11.8% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, BioTelemetry ( BEAT), up 22.1%, Dynatronics Corporation ( DYNT), up 11.5%, Retractable Technologies ( RVP), up 11.3% and Lifevantage Corporation ( LFVN), up 8.9%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern